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Papillarycarcinomaisaprominentmalignancyoriginatingfromfollicularcells.Thisdiseasegenerallyshowsanindolentcharacter,
butpatientsdemonstratingcertainclinicopathologicalfeatureshaveadireprognosis.Atpresent,Westerncountriesadoptedalmost
routinetotalthyroidectomywithradioactiveiodine(RAI)ablation,whilelimitedthyroidectomywithextensiveprophylacticlymph
node dissection has traditionally been performed for most patients in Japan. Recently, accurate evaluation of carcinoma stage can
beperformedonpreoperativeimagingstudies,especiallyonultrasonography.Itisthereforeimportanttotreatpapillarycarcinoma
patients depending on clinicopathological features rather than in a stereotyped fashion. In this paper, appropriate extension of
thyroidectomy and lymph node dissection is discussed based on Western and recently published Japanese guidelines and the
experience in Kuma Hospital.
1.Introduction
Papillary carcinoma is the most common malignancy arising
from thyroid follicular cells. In Western countries, papillary
carcinomacomprises85%inwhitesand72%inblacks[1,2].
According to an investigation of the Japanese Society of
Thyroid Surgeons (JSTS) in 2004, the incidence of papillary
carcinoma in Japan was 93%, which was higher than that in
Western countries, possibly because of suﬃcient amounts of
iodineintheJapanesediet.Generally,ithasanindolentchar-
acter, but cases showing certain clinicopathological features
are progressive and show a dire prognosis. Frequent multi-
plicity in the thyroid and metastasis to the regional lymph
nodes is prominent biological characteristics of papillary
carcinoma. Therefore, not only the extent of thyroidectomy
butalso that oflymph node dissection remains controversial.
In Western countries, total (or near total) thyroidectomy
has been almost routinely performed because the serum
thyroglobulin level can be used as a marker of recurrence
or persistent disease, and radioactive iodine (RAI) ablation
can be performed as an adjuvant therapy. Moreover, RAI
therapy can be immediately performed when the thy-
roglobluin level becomes elevated or recurrence is clinically
detected. In Japan, however, limited thyroidectomy such as
subtotal thyroidectomy and lobectomy with isthmectomy
has been traditionally adopted as the standard. This is
partially because the capacity to perform RAI therapy is
limited due to legal restrictions, and RAI therapy is not
considered cost eﬀective by the healthcare system in Japan.
Furthermore, it is also because Japanese endocrine surgeons
are empirically aware that most papillary carcinomas are
indolent and their prognoses are generally excellent. Limited
thyroidectomy decreases the incidence of severe compli-
cations such as bilateral recurrent laryngeal paralysis and
persistent hypoparathyroidism, and patients may not require
the administration of L-thyroxine.
In contrast, lymph node dissection is not actively per-
formed in Western countries. In Japan, however, extensive
prophylactic lymph node dissection not only in the central
but also lateral compartment has been widely adopted. This
is because the organ to which papillary carcinoma most
frequently recurs is the lymph node [3], and prophylactic
lymph node dissection can decrease the recurrence rate of
carcinoma.
From early in the 1990s, the elevated resolution power
of ultrasonography has facilitated the accurate evaluation of2 Journal of Thyroid Research
Table 1: Indication for total thyroidectomy for patients with papillary carcinoma in various guidelines and in our department.
Kuma Hospital All patients except T1N0M0 or microcarcinoma extending only to muscles mucosal layer of the
esophagus and recurrent laryngeal nerve
JSTS/JAES
Strongly recommended −−−−−→ Tumor size >5cm, extrathyroid extension to the trachea or esophagus,
large number of clinical lymph node metastasis, lymph node metastasis >3cm, and distant metastasis
Moderately recommended − −−−−− → Tumor size >4cm, clinical lymph node metastasis
ATA All patients except low-risk microcarcinoma
BTA Most patients, especially for those with tumor size >1cm, multifocal disease, extrathyroid extension,
familial disease, clinical lymph node metastasis, and radiation history
NCCN
Age <15yrs or >45yrs, radiation history, distant metastasis, bilateral nodularity, extrathyroidal
extension, Tumor size >4cm, clinical lymph node metastasis, and aggressive variant (however, also for
other cases, total thyroidectomy is the most common)
thyroid carcinoma by demonstrating the size and location of
primary lesions and lymph node metastases. Based on the
prognostic dataofpatients whounderwent surgeryin theera
of routine ultrasonography, it may be the time to revise the
standards regarding the optimal extent of thyroidectomy and
lymphnodedissectionforpapillarycarcinoma.Inthispaper,
we compare the strategies of thyroidectomy and lymph node
dissection among Western and Japanese guidelines as well
as our experience in order to consider the most appropriate
surgical designs for papillary carcinoma patients.
2. Thyroidectomy
Total thyroidectomy is almost routinely recommended by
Western guidelines such as those of National Comprehensive
Cancer Network (NCCN), ATA, and BTA [4–6].
As indicated in the introduction, limited thyroidectomy
has been more widely adopted than total thyroidectomy in
JapanbecauseofthelimitedcapacitytoperformRAItherapy,
and the policy of Japanese endocrine surgeons that limited
thyroidectomy is adequate for most papillary carcinoma
patients. In the Japanese guideline recently published, it is
indicated that, for patients with T1N0M0 according to UICC
TNM classiﬁcation system, hemithyroidectomy is acceptable
and adequate [7]. Indeed, one Japanese study showed that
10-year disease-free survival (DFS) rates of 2638 solitary
T1N0M0 patients were excellent at 97% even though 60%
of these patients underwent limited thyroidectomy [8]. The
incidence of recurrence to the remnant thyroid in patients
who underwent limited thyroidectomy was only 1%. Distant
metastasis was detected only in 4 patients (0.2%). Two
patients died of carcinoma due to the growth of local or
distant recurrence. However, patients who underwent total
thyroidectomy are easier to follow than those receiving lim-
ited thyroidectomy because, as indicated above, thyroglob-
ulin level can be a marker of recurrence, and RAI therapy
can be immediately performed for carcinoma recurrence.
Therefore, total thyroidectomy should be the ﬁrst line for
patients with high-risk features predicting poor disease-
free and cause-speciﬁc survival rates. In our guideline,
total thyroidectomy is strongly recommended for patients
having tumor size larger than 5cm, large number of clinical
lymph node metastases detected on imaging studies, lymph
node larger than 3cm, signiﬁcant extrathyroid extension, or
distant metastasis at surgery [7]. Such patients are regarded
as high risk and considered likely to show recurrence to
local and/or distant organs. Furthermore, our guideline also
described that total thyroidectomy is preferable also for
patients having tumor larger than 4cm or clinical lymph
node metastasis.
Currently, our indication for total thyroidectomy is
wider than that in the Japanese guideline but still narrower
than that in Western guidelines. We recommend total
thyroidectomy for all patients except low-risk patients such
as solitary T1N0M0 patients and those with microcarcinoma
extending only to the muscles, muscle layer of the esophagus,
or recurrent laryngeal nerve. Indeed, the incidence of
total thyroidectomy is increasing in our department mainly
because of the ease of postoperative followup.
Table 1 summarizes the indications for total thyroidec-
tomyinWesternandJapaneseguidelinesandinourhospital.
3. Lymph Node Dissection
Regional lymph nodes are located in the three com-
partments; central, lateral, and mediastinal compartments.
Although one study recommended prophylactic mediastinal
dissection in papillary carcinoma showing contralateral
lateral node metastasis [9], generally this compartment is
dissected only when radiologic evidence of metastasis is
detected. In this paper, indications for dissection of central
and lateral compartments are described.
3.1. Central Compartment. Of the three compartments, the
central compartment is the most adjacent to the thyroid.
This compartment can be dissected without extension of the
wound for thyroidectomy or exacerbation of postoperative
complications such as neck discomfort and pain. In an
investigation of 5805 patients who underwent central node
dissection, the positive predictive value and speciﬁcity of
preoperative ultrasonography were high at 92% and 98%,
respectively, but negative predictive value and sensitivity
were terribly low at 37% and 12%, respectively [3]. This
indicates that, of patients diagnosed as negative on ultra-
sonography, 63% are diagnosed as having positive lymph
nodes in this compartment on pathological examination.Journal of Thyroid Research 3
Table 2: Indications for prophylactic central node dissection for patients with papillary carcinoma in various guidelines and in our
department.
Kuma Hospital Routinely recommended
JSTS/JAES Routinely recommended
ATA May be performed for T3 or T4 patients
BTA Male gender, age >45yrs, tumor size >4cm, and extracapsular or extrathyroidal disease
NCCN
Can be considered for patients with age <15yrs or >45yrs,
radiation history, distant metastasis, bilateral nodularity, extrathyroidal
extension, tumor size >4cm, and aggressive variant
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Figure 1: Carcinoma recurrence rates for patients who did not
show clinical node metastasis (N0), those with clinical central node
metastasis (N1a), and those with lateral node metastasis (N1b).
Patientshavingsigniﬁcantextrathyroidextensionweredeletedfrom
the series.
This is possibly because the air-ﬁlled trachea, clavicle, and
menubrium of the sternum disrupt the accurate depiction
on ultrasonography.
Patients having clinical node metastasis not only to
the lateral but also to the central compartment are more
likely to show carcinoma recurrence than patients without
clinical node metastasis (Figure 1)[ 10]. Therefore, careful
therapeutic node dissection should be performed for such
patients. However, there are discrepant data on improving
the prognosis of central node dissection [11–18], and there
are no studies comparing prognoses between patients who
underwent prophylactic central node dissection and did not
undergo that. Therefore, it is still debatable whether prophy-
lactic central node dissection is of clinical signiﬁcance.
Western guidelines do not recommend routine prophy-
lactic central node dissection [4–6]. In contrast, the Japanese
guideline recommends routine prophylactic central node
dissection [7]. This is because, as indicated above, central
node metastasis is diﬃcult to evaluate preoperatively, and
reoperation for recurrence to this compartment may cause
severe complications suchas recurrent laryngeal nerve injury
andpersistenthypoparathyroidism.Ourdepartmenthasalso
Table 3: Relationship between metastasis to the central and lateral
compartments in 3940 patients.
Lateral node metastasis (%)
Negative Positive Total
Central node
metastasis (%)
Negative 21 11 32
Positive 15 53 68
36 64 100
traditionally adopted the same procedure for central node
dissectionasoutlinedintheJapaneseguideline.TheJapanese
guideline also indicates that in patients who undergo
hemithyroidectomy, the pretracheal and peritracheal nodes
ipsilateral to the primary lesion as well as the Delphian nodes
should be dissected, while dissection of peritracheal nodes
contralateral to primary lesion is not mandatory. We agree
with this guideline because, according to our data, central
node dissection in the contralateral lobe did not improve the
prognosis of patients with microcarcinoma [8].
The recommended management of centralcompartment
dissection in the Japanese guideline and in our department
is in sharp contrast to that in Western guidelines. Table 2
summarizes the strategies in the guidelines and in our
department.
3.2. Lateral Compartment. The lateral compartment is more
distant from the thyroid than the central compartment.
In order to dissect this compartment, wound extension is
necessary and, therefore, we have considered that papillary
carcinoma initially metastasizes to the central compartment
and, thereafter, metastasizes to the lateral compartment.
However, as shown in Table 3, the incidence of central-
negative but lateral-positive patients was similar to that
of central-positive but lateral-negative patients [3, 19]. It
is thus suggested that papillary carcinoma shows similar
incidences of initially metastasizing to the central and lateral
compartments.
For patients showing clinical lateral node metastasis
(N1b), therapeutic lateral node dissection is mandatory.
Clinical lateral node metastasis is an important and inde-
pendent prognostic factor [3, 20]. Especially, patients having
metastatic nodes larger than 3cm or extranodal tumor
extension have a signiﬁcantly worse disease-free survival and
cause-speciﬁcsurvival[10,21].Thus,carefulnodedissection4 Journal of Thyroid Research
Table 4: Relationship between lateral node metastasis and tumor
size in 1231 patients who were diagnosed as negative for metastasis
on preoperative ultrasonography but underwent prophylactic lat-
eral node dissection.
Number of metastases (%)
Tumor size (cm) 0 1–4 5 or more Total
1.0 or less 78 (59.5) 43 (32.8) 10 (7.6) 131
1.1–2.0 191 (47.9) 143 (35.8) 65 (16.3) 399
2.1 or more 172 (24.5) 299 (42.7) 230 (32.8) 701
Table 5: Indications for prophylactic lateral node dissection for
patients with papillary carcinoma in various guidelines and in our
department.
Kuma Hospital Tumor size > 3 cm, extrathyroid extension
JSTS/JAES Not determined, although its signiﬁcance
in reducing recurrence is recognized
ATA Not recommended
BTA Not recommended
NCCN Not recommended
is necessary in order to prevent recurrence at least to the
compartment that had previously been dissected.
However, the indications for prophylactic lateral node
dissection remain debatable. Diagnostic accuracy for lateral
node metastasis on ultrasonography is somewhat better
than that for central node metastasis, but the negative
predictive value and sensitivity remain low at 43% and 29%,
respectively [3]. Furthermore, the incidence of lateral node
metastasis for cases that are not preoperatively diagnosed as
negativeincreaseswithtumorsize,andabout75%ofpatients
with primary lesions larger than 2cm demonstrated latent
metastasis in this compartment (Table 4)[ 22]. If prophy-
lactic lateral node dissection is not performed, metastatic
nodesinthiscompartmentremainundissectedataveryhigh
incidence. Since Japanese endocrine surgeons are empirically
aware of the high incidence of node metastasis to the lateral
compartment, they actively perform prophylactic lateral
node dissection, although none of the Western guidelines
recommend this [4–6]. However, it is a separate issue
whether these latent metastatic nodes become a clinical issue
that later aﬀects patient prognosis. Indeed, previous studies,
including those from Japan, showed discrepant results for
the signiﬁcance of lateral node dissection [22–30]. Based
on these, Japanese guideline recognizes that prophylactic
lateral node dissection decreases the risk of recurrence and
improves disease-free survival but does not clearly state
its indication. Our department recommends prophylactic
lateral node dissection for patients having a primary lesion
larger than 3cm or signiﬁcant extrathyroid extension,
because these patients show a signiﬁcantly worse lymph
node metastasis-free survival even though they underwent
prophylactic lateral node dissection (Figures 2(a) and 2(b))
[22]. Another department in Japan showed that prophylactic
lateralnodedissectionispreferableforpatienthavingtumors
greater than 4cm or with distant metastasis [28]. Indications
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Figure 2: (a) Lymph node (LN) recurrence rates for patients
with tumors 3cm or larger and those with tumors less than 3cm
who underwent central and prophylactic lateral node dissection.
(b) Lymph node (LN) recurrence rates for patients with and
without signiﬁcant extrathyroid extension who underwent central
and prophylactic lateral node dissection.
of prophylactic lateral node dissection based on Western
guidelines, Japanese guideline, and our department are
summarized in Table 5.
4. Conclusions
Recently, in Japan, there has been a developing opinion
that total thyroidectomy would be preferable for papillary
carcinoma patients demonstrating high-risk features, and
prophylactic lateral node dissection is unnecessary for low-
risk patients. In contrast, routine RAI ablation after total
thyroidectomy for low-risk patients has come under review
in Western countries, and in the BTA guideline, risk of
second malignancy is described, indicating that routine totalJournal of Thyroid Research 5
thyroidectomy for low-risk patients may become less signiﬁ-
cant [6]. We have an impression that strategies for treatment
of thyroid carcinoma, including papillary carcinoma, in
Western countries and Japan are coming closer to each other.
Due to the high resolution power of ultrsonography,
evaluation of primary lesions, including size, number and
location, and lymph node metastases, can be accurately
performed. Under such circumstances, we consider that the
treatment of papillary carcinoma should be determined on
a case-by-case basis rather than in a stereotyped fashion.
Needless to say, total thyroidectomy is mandatory for high-
risk patients predicted to develop carcinoma recurrence in
high incidences. It is, however, doubtful whether routine
total thyroidectomy with RAI ablation is appropriate for the
treatment of papillary carcinoma. For example, it is now
evident that total thyroidectomy is not needed for T1N0M0
carcinoma unless there are no pathological lesions in the
contralateral lobe on ultrasonography [8]. The indications
for total thyroidectomy in the Japanese guideline are nar-
rower than those in Western guidelines. In our department,
the prevalence of total thyroidectomy is increasing, but the
indications are still stricter than those in Western guidelines.
This is based on our policy that low-risk patients show
an excellent prognosis even though they undergo limited
thyroidectomy.
Regarding lymph node metastasis, patients having clini-
cal node metastasis detectable on ultrasonography are likely
to show recurrence even when they undergo therapeutic
lymph node dissection. Unfortunately, the incidence of
recurrence to the compartments that had previously been
dissected is similar to that of recurrence to the compartment
that had not been dissected [3]. Therefore, very careful node
dissection is necessary for such patients.
It is important to note that ultrasonography very
often overlooks lymph node metastasis, and the indications
for prophylactic node dissection come into question. The
Japanese guidelines and our department policy recommend
routine central node dissection, which is in sharp contrast
to Western guidelines. In our opinion, this should be
routinely performed in order to prevent recurrence to this
compartment. Reoperation for recurrence to this compart-
ment may induce severe complications such as persistent
hypoparathyroidsm and recurrent laryngeal injury. The
Japanese guideline does not clearly describe the indica-
tions for prophylactic lateral node dissection although the
guideline recognizes the eﬀectiveness of this approach to
improving disease-free survival. This may reﬂect the fact that
almost routine lateral node dissection was performed in the
past. However, our department recommends prophylactic
lateral node dissection for patients having tumors greater
than 3cm or signiﬁcant extrathyroid extension. Although
there are no comparative data, such patients show a high
incidence of lymph node recurrence even though they
undergo prophylactic lateral node dissection. Western guide-
linesdonotrecommendprophylacticlateralnodedissection,
which may be because of a diﬀerence in the lymph node
recurrence rates considered acceptable by Western countries
and in our department.
In summary, we described the extent of thyroidectomy
and lymph node dissection recommended by the Japanese
guideline and our department and compared these with
those outlined in Western guidelines. We expect that treat-
ment strategies in Western countries and Japan will become
closer to each other in the future, providing the optimal
treatment for patients around the world.
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